Key result
Aquapheresis shows no clear benefit over pharmacological decongestion to support routine clinical use.
Why the study?
Fluid overload and persistent congestion are common and clinically important problems in acute decompensated heart failure, prompting a review of the mechanism, clinical applications, comparative evidence, safety, practical considerations, and limitations of aquapheresis.
Does aquapheresis improve decongestion and clinical outcomes compared to pharmacological therapy in patients with acute decompensated heart failure and fluid overload?
Does aquapheresis improve decongestion and clinical outcomes compared to pharmacological therapy in patients with acute decompensated heart failure and fluid overload?
Current evidence does not support routine aquapheresis over pharmacological decongestion in acute decompensated heart failure, reserving it as a selective adjunct for refractory congestion.
Answers are grounded in this paper and cite their sources.
Does not support routine aquapheresis over diuretics; leaves open selective use in refractory cases for future trials.
Background Fluid overload and persistent congestion are common and clinically important problems in acute decompensated heart failure. Isolated extracorporeal ultrafiltration, including aquapheresis systems, provides controlled removal of plasma water and sodium without the broader solute clearance of kidney replacement therapy. Objective To review the mechanism, clinical applications, comparative evidence, safety, practical considerations, and limitations of aquapheresis for fluid overload. Methods This narrative review synthesizes the available clinical literature, with emphasis on randomized trials, observational studies, and clinically relevant reports addressing decongestion, renal outcomes, adverse events, and implementation. Results Aquapheresis can achieve controlled fluid removal in selected patients with persistent congestion. However, randomized trials have produced mixed results. UNLOAD demonstrated greater short-term fluid and weight loss than intravenous diuretics, whereas the Cardiorenal Rescue Study in Acute Decompensated Heart Failure found stepped pharmacological therapy superior for the primary composite endpoint and reported more worsening renal function and serious adverse events with ultrafiltration. Aquapheresis versus intravenous diuretics and hospitalization for heart failure was terminated early and did not establish superiority. Practical limitations include vascular-access and circuit complications, anticoagulation requirements, monitoring needs, staffing, and cost. Conclusion Current evidence does not support routine use of aquapheresis as a replacement for pharmacological decongestion or kidney replacement therapy. It may be considered a selective adjunct for patients with clinically significant, persistent fluid overload despite appropriate pharmacological management, with careful attention to renal function, hemodynamic status, and treatment-related complications.
No takes yet. Share an insight, caveat, or question.
Siddiqui et al. (2026) conducted a review in Acute decompensated heart failure with fluid overload and persistent congestion. Aquapheresis (isolated extracorporeal ultrafiltration) vs. Intravenous diuretics / stepped pharmacological therapy / kidney replacement therapy was evaluated on Decongestion (fluid and weight loss), renal outcomes, and adverse events. Aquapheresis achieves controlled fluid removal in persistent congestion, but randomized trials show mixed results and do not support its routine use over pharmacological decongestion.
Synapse has enriched 10 related papers. Consider them for comparative context: